Kulkarni Samarth — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

Kulkarni Samarth has filed 3 SEC Form 4 filings across 3 companies in the last 90 days — selling. Lifetime open-market sales: $14.21M.

Profile

Kulkarni Samarth

Samarth Kulkarni is the Chief Executive Officer of CRISPR Therapeutics AG, a leading gene editing company known for its innovative CRISPR/Cas9 technology. Under his leadership, the company focuses on developing therapeutics for genetically defined diseases.

RoleInsider
Notability50/100

Board memberships

Awards & honors

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-03-24CRSPCRISPR Therapeutics AGS — Open-market sale10.0K$46.78$469K
2026-03-24CRSPCRISPR Therapeutics AGM — Option exercise19.7K—
2026-03-17CRSPCRISPR Therapeutics AGS — Open-market sale10.3K$48.26$499K
2026-03-17CRSPCRISPR Therapeutics AGM — Option exercise20.6K—
2026-03-12CRSPCRISPR Therapeutics AGS — Open-market sale9.8K$52.80$517K
2026-03-12CRSPCRISPR Therapeutics AGM — Option exercise19.2K—
2026-02-20CRSPCRISPR Therapeutics AGS — Open-market sale7.0K$52.58$366K
2026-02-20CRSPCRISPR Therapeutics AGM — Option exercise13.2K—
2026-01-22CRSPCRISPR Therapeutics AGS — Open-market sale [10b5-1]60.0K$60.23$3.61M
2026-01-22CRSPCRISPR Therapeutics AGS — Open-market sale [10b5-1]8.6K$52.10$446K
2026-01-22CRSPCRISPR Therapeutics AGS — Open-market sale [10b5-1]21.4K$51.61$1.11M
2025-12-22CRSPCRISPR Therapeutics AGG — Bona-fide gift30.0K$0.00
2025-10-20CRSPCRISPR Therapeutics AGS — Open-market sale50.9K$67.91$3.46M
2025-10-20CRSPCRISPR Therapeutics AGM — Option exercise100.0K—
2025-10-13CRSPCRISPR Therapeutics AGS — Open-market sale4.2K$66.60$283K
2025-10-13CRSPCRISPR Therapeutics AGM — Option exercise8.3K—
2025-09-17CRSPCRISPR Therapeutics AGG — Bona-fide gift6.0K$0.00
2025-08-16CRSPCRISPR Therapeutics AGS — Open-market sale13.1K$58.15$761K
2025-08-16CRSPCRISPR Therapeutics AGM — Option exercise25.0K—
2024-12-27CRSPCRISPR Therapeutics AGM — Option exercise13.8K$16.21$223K

Companies — Last 90 Days

Frequently Asked Questions

Who is Kulkarni Samarth?

Samarth Kulkarni is the Chief Executive Officer of CRISPR Therapeutics AG, a leading gene editing company known for its innovative CRISPR/Cas9 technology. Under his leadership, the company focuses on developing therapeutics for genetically defined diseases.…

How many SEC Form 4 filings has Kulkarni Samarth submitted recently?

3 primary Form 4 filings in the last 90 days, covering 3 companies.

Has Kulkarni Samarth been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 14 open-market sales ($14.21M) across all tracked filings.

Where can I see all of Kulkarni Samarth's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live Kulkarni Samarth profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.